In IBC, the higher numbers of CD1a+ and mature CD83+ DCs are associated with smaller tumor size [27,29], higher overall survival and a lower risk of relapse in triple-negative BC after neoadjuvant chemotherapy without pathological complete response [37]. This evidence concerns the gene CD83 and breast cancer.